About novabay pharmaceuticals - NBY
NovaBay Pharmaceuticals, Inc. engages in the development and sales of scientifically-created and clinically-proven eyecare and skincare. Its products include Avenova, NeutroPhase and DERMAdoctor. The company was founded on January 19, 2000 and is headquartered in Emeryville, CA.
NBY At a Glance
NovaBay Pharmaceuticals, Inc.
2000 Powell Street
Emeryville, California 94608-1866
| Phone | 1-510-899-8800 | Revenue | 9.78M | |
| Industry | Pharmaceuticals: Major | Net Income | -7,210,000.00 | |
| Sector | Health Technology | Employees | 14 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
NBY Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.209 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.716 |
| Enterprise Value to Sales | 0.336 |
| Total Debt to Enterprise Value | 0.508 |
NBY Efficiency
| Revenue/Employee | 698,642.857 |
| Income Per Employee | -515,000.00 |
| Receivables Turnover | 25.144 |
| Total Asset Turnover | 0.356 |
NBY Liquidity
| Current Ratio | 0.681 |
| Quick Ratio | 0.412 |
| Cash Ratio | 0.151 |
NBY Profitability
| Gross Margin | 66.261 |
| Operating Margin | -50.854 |
| Pretax Margin | -73.714 |
| Net Margin | -73.714 |
| Return on Assets | -26.247 |
| Return on Equity | -452.747 |
| Return on Total Capital | -467.272 |
| Return on Invested Capital | -288.285 |
NBY Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 108.36 |
| Total Debt to Total Assets | 3.642 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 45.949 |